Technical Analysis for ONCO - Onconetix, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| 20 DMA Support | Bullish | -6.10% | |
| Calm After Storm | Range Contraction | -6.10% | |
| Inside Day | Range Contraction | -6.10% | |
| Wide Bands | Range Expansion | -6.10% |
| Alert | Time |
|---|---|
| Fell Below 50 DMA | about 8 hours ago |
| 50 DMA Support | about 9 hours ago |
| Down 10% | about 9 hours ago |
| 60 Minute Opening Range Breakdown | about 9 hours ago |
| Fell Below Previous Day's Low | about 10 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/30/2024
Onconetix, Inc. (formerly Blue Water Biotech, Inc. (BWV)) is a commercial stage biotechnology company focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The Company currently has Entadfi®, an FDA approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix®, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology FDA Disorders Prostate Cancer Urology Benign Prostatic Hyperplasia Bph Men's Health Prostate Treatment Of Benign Prostatic Hyperplasia
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology FDA Disorders Prostate Cancer Urology Benign Prostatic Hyperplasia Bph Men's Health Prostate Treatment Of Benign Prostatic Hyperplasia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Date | Title |
|---|---|
| Jan 26 | US Stocks Mixed; Core PCE Prices Rise In December |
| Indicator | Value |
|---|---|
| 52 Week High | 1.21 |
| 52 Week Low | 0.1001 |
| Average Volume | 6,261,005 |
| 200-Day Moving Average | 0.24 |
| 50-Day Moving Average | 0.15 |
| 20-Day Moving Average | 0.16 |
| 10-Day Moving Average | 0.16 |
| Average True Range | 0.04 |
| RSI (14) | 48.98 |
| ADX | 49.41 |
| +DI | 43.82 |
| -DI | 13.40 |
| Chandelier Exit (Long, 3 ATRs) | 0.21 |
| Chandelier Exit (Short, 3 ATRs) | 0.24 |
| Upper Bollinger Bands | 0.20 |
| Lower Bollinger Band | 0.13 |
| Percent B (%b) | 0.41 |
| BandWidth | 47.35 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0001 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.18 | ||||
| Resistance 3 (R3) | 0.18 | 0.17 | 0.17 | ||
| Resistance 2 (R2) | 0.17 | 0.16 | 0.17 | 0.17 | |
| Resistance 1 (R1) | 0.16 | 0.16 | 0.17 | 0.16 | 0.17 |
| Pivot Point | 0.15 | 0.15 | 0.16 | 0.16 | 0.15 |
| Support 1 (S1) | 0.15 | 0.15 | 0.15 | 0.15 | 0.14 |
| Support 2 (S2) | 0.14 | 0.15 | 0.14 | 0.14 | |
| Support 3 (S3) | 0.14 | 0.14 | 0.14 | ||
| Support 4 (S4) | 0.14 |
